Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Elecsys Hepatitis B Surface Antigen Quantitative Assay: Performance Evaluation and Correlation with Hepatitis B Virus DNA during 96 Weeks of Follow-up in Chronic Hepatitis B Patients

  • Lee, Hyun Ji (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital) ;
  • Kim, Shine Young (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital) ;
  • Lee, Sun Min (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital) ;
  • Heo, Jeong (Department of Internal Medicine, Pusan National University School of Medicine Pusan National University Hospital) ;
  • Kim, Hyung Hoi (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital) ;
  • Chang, Chulhun L. (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital) ;
  • Lee, Eun Yup (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital) ;
  • Son, Han Chul (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital)
  • Published : 2012.11.01
⟨ Previous Next ⟩

Abstract

Background: Treatment for chronic hepatitis B aims to suppress virus replication and virus sequestration in hepatocytes. Covalently closed circular (ccc) DNA is the template for transcription of viral genes and is responsible for viral persistence. However, limited data are available for quantification of hepatitis B surface antigen (HBsAg) in Korea. Methods: We evaluated the Elecsys HBsAg II quant assay (Roche Diagnostics, USA) for within-run, between-run, and between-day precisions, linearity, carryover, and clinical specificity. In total, 156 serum samples were evaluated for correlation between HBsAg and hepatitis B virus (HBV) DNA. Serial samples were obtained from 10 patients at 0, 12, 24, 48, 72, and 96 weeks during follow-up. Results: The assay detected HBsAg in a linear range of 0.5-48,696 IU/mL. Within-run, between-run, and between-day CVs were 2.9-4.1%, 0-1.5%, and 1.5-4.9%, respectively. Cross-reactivity between potentially interfering substances was absent, and the carryover rate was 0.00002%. The correlation of measurements between the Elecsys assay and HBV DNA PCR was weak (r=0.438, P =0.002). For predicting virologic response, cutoff values of 10,275 IU/mL and 3,846 IU/mL at 12 and 24 weeks after treatment initiation showed positive predictive values of 77.1% and 85% and negative predictive values of 84.6% and 50%, respectively. Conclusions: The Elecsys HBsAg II quant assay showed good performance for precision, linearity, carryover rate, and specificity. HBsAg level at baseline, 12 weeks, and 24 weeks after treatment initiation can predict virologic response, and the assay can be used for HBsAg quantification in clinical practice.

Keywords

References

  1. Lin LY, Wong VW, Zhou HJ, Chan HY, Gui HL, Guo SM, et al. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg- negative patients. J Med Virol 2010;82:1494-500. https://doi.org/10.1002/jmv.21863
  2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. https://doi.org/10.1056/NEJM199712113372406
  3. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52:508-13. https://doi.org/10.1016/j.jhep.2010.01.007
  4. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22. https://doi.org/10.1016/j.jhep.2010.01.014
  5. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44. https://doi.org/10.1002/hep.23571
  6. Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011;51:175-8. https://doi.org/10.1016/j.jcv.2011.04.005
  7. Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011;50:292-6. https://doi.org/10.1016/j.jcv.2010.12.008
  8. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of puantitative measurement methods: Approved guideline, EP5-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2004.
  9. Tholen DW. Evaluation of linearity using the newly approved NCCLS EP6-A protocol. Clin Lab News 2004;30:10-2.
  10. National Committee for Clinical Laboratory Standards. Preliminary evaluation of quantitative clinical laboratory methods: Approved guideline, EP10-A2. Second edition. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
  11. National Committee for Clinical Laboratory Standards. Protocols for determination of limits of detection and limits of quantitation: Approved guideline EP17-A. Wayne, PA: National Committee for Clinical and Laboratory Standards, 2004.
  12. Glass DC and Gray CN. Estimating mean exposures from censored data: exposure to benzene in the Australian petroleum industry. Ann Occup Hyg 2001;45:275-82.
  13. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011;55:1121-31. https://doi.org/10.1016/j.jhep.2011.06.006
  14. Moucari R and Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011;31(S1):122-8. https://doi.org/10.1111/j.1478-3231.2010.02390.x
  15. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217-22. https://doi.org/10.1016/j.jviromet.2003.10.002
  16. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, et al. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci 2008;53:2995-8. https://doi.org/10.1007/s10620-008-0263-5
  17. Weigand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, et al. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 2008;13:547-54.
  18. Chen J, Wang Z, Guo Y, Peng J, Sun J, Ahmed CS, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 2009;81:88-91. https://doi.org/10.1016/j.antiviral.2008.09.005
  19. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot- Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7. https://doi.org/10.1002/hep.22744
  20. Cho YK and Song BC. New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B. Korean J Gastroenterol 2011;57:144-9. https://doi.org/10.4166/kjg.2011.57.3.144
  21. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462-8. https://doi.org/10.1016/j.cgh.2007.09.005
  22. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatology Int 2011 [Epub ahead of print].
  23. Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B. J Med Virol 2011;83:1178-86. https://doi.org/10.1002/jmv.22089
  24. Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010;48:22-6. https://doi.org/10.1016/j.jcv.2010.02.014

Cited by

  1. Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry vol.34, pp.1, 2014, https://doi.org/10.3343/alm.2014.34.1.7
  2. Prognoses of patients with acute-on-chronic hepatitis B liver failure are closely associated with altered SOCS1 mRNA expression and cytokine production following glucocorticoid treatment vol.11, pp.4, 2012, https://doi.org/10.1038/cmi.2014.23
  3. Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B vol.20, pp.3, 2012, https://doi.org/10.3350/cmh.2014.20.3.274